PMOS/PCOS Cysts

You went in for a transvaginal ultrasound because your cycles have been irregular for months. The technician slid the wand into position, paused at the screen, and used a phrase that made your stomach drop: "polycystic ovaries." You spent the rest of the day on your phone looking up images of ovarian cysts — fluid-filled sacs, surgical removal, ruptures, emergency-room presentations — and now you cannot stop wondering when one of them is going to burst.

Here is what nobody told you in that appointment: the "cysts" they were referring to are not cysts at all. They are small, normal ovarian follicles that stalled in their development. They do not burst. They do not require surgery. And the name that drove your panic — polycystic ovary syndrome — was a misnomer from the beginning.

Polycystic ovary syndrome (PCOS) — also called PMOS in recent medical literature — is the condition you may have been diagnosed with. In 2026, after an unprecedented multistep global consensus process involving 56 academic, clinical, and patient organizations and over 14,360 stakeholder responses, the condition was formally renamed to polyendocrine metabolic ovarian syndrome (PMOS) (Teede et al. 2026). The reason the name was changed is the exact reason you panicked in that ultrasound room. The old name pointed at the ovaries and the "cysts," when the real driver of the condition lives in your metabolism, your brain, and your endocrine system as a whole. The cyst was never the story.

This article walks through what is actually happening inside your ovaries when an ultrasound calls them polycystic, why a simple blood test has replaced the ultrasound for many women, why this finding alone is not a diagnosis, and what the underlying metabolic loop has to do with the appearance of those follicles.

So if they're not cysts, what is the ultrasound actually showing?

To understand what an ultrasound is picking up in PCOS, you first have to know how a normal menstrual cycle works at the ovary level.

Every month, a group of small, fluid-filled envelopes called follicles begins to mature inside your ovaries. Each follicle holds a single egg. As the cycle progresses, the signaling network between your brain and your ovaries selects one follicle to become dominant. That dominant follicle grows large, eventually ruptures, and releases its egg — the moment of ovulation. The remaining smaller follicles that did not get selected dissolve quietly and get reabsorbed.

In PCOS, that selection process breaks down. The hormonal signals required for one follicle to mature and rupture are scrambled. Without the correct signal, no follicle becomes dominant. The group of follicles that started developing simply arrest at a small size and stay parked in the ovary. Month after month, more follicles enter that arrested state and accumulate along the outer rim of the ovary.

When a sonographer looks at your ovary in this state, they see a ring of small, similarly-sized follicles around the periphery. Older ultrasound textbooks described this pattern as a "string of pearls." The clinical term is polycystic ovarian morphology — meaning the ovary has many small follicles visible on ultrasound. The word "cyst" was borrowed for these tiny follicles because they appear, on the imaging screen, as small fluid-filled circles. Linguistically, that is what a cyst is in radiology — a fluid-filled cavity.

But a true ovarian cyst is something fundamentally different. Pathological ovarian cysts — like hemorrhagic cysts, dermoid cysts, endometriomas, or large functional cysts — are distinct structural growths that can become several centimeters across, cause sharp localized pelvic pain, and occasionally require surgical intervention. The follicles in PCOS are not growths. They are normal anatomy that simply stalled. They do not rupture, they do not require surgery, and they are not inherently dangerous on their own.

This anatomical reality has been well-documented for decades. Foundational ultrasound research in the 1980s demonstrated that the "polycystic" appearance is the structural footprint of chronic missed ovulation — it shows up in the majority of women who are not ovulating regularly, whether or not they have the other syndrome symptoms (Adams et al. 1986). The morphology is a downstream finding. It is the picture your ovary takes when ovulation has been stalled for months.

Why did the old name PCOS lock so much of the conversation onto the ovaries?

The "cyst" framing did real harm. The 2026 PMOS rename consensus called it out directly: anchoring clinical and public understanding on ovarian "cysts" obscured the underlying metabolic and endocrine drivers and led to a fragmented, gynecology-first approach to care that missed the systemic nature of the condition.

There were two specific failure modes the old name created.

First, overdiagnosis in young women and adolescents. Multifollicular ovaries are entirely normal in healthy teenagers as their reproductive systems mature — the developing brain-ovary signaling has not yet locked into a consistent monthly rhythm, so multiple follicles linger longer than they will in adulthood. Under the old PCOS terminology, countless adolescents were sent for transvaginal ultrasounds, found to have multifollicular ovaries that were entirely age-appropriate, and were given a lifelong diagnosis that they did not actually have. To prevent that error, current diagnostic guidelines now strictly exclude the use of ultrasound for diagnosing adolescents — an adolescent must present with both irregular cycles and clear clinical signs of androgen excess, like severe acne or unwanted facial hair growth, to be diagnosed (Teede et al. 2023).

Second, the cyst framing pulled the clinical conversation toward the ovaries when the actual drivers were upstream. If you have insulin resistance, your "cysts" are a downstream effect of the metabolic loop, not the cause of anything. Surgically removing them — which used to be tried — accomplishes nothing because you cannot cut away a feedback loop. The new PMOS name signals this directly: poly-endocrine (multiple hormone systems), metabolic (the metabolism is part of the disease), ovarian (the ovaries are involved but not the whole story).

The new terminology was selected with care. During the consensus process, "reproductive" was considered and rejected because it carries social stigmatization in cultures where fertility is highly valued; "ovulatory" was rejected because it was too narrow and loses relevance after menopause. "Ovarian" was kept because it accurately names the organ involved without overstating its primacy. To prevent disruption to clinical records, billing systems, and ongoing patient care, the rename includes a three-year evolutionary transition period during which the new nomenclature is being integrated into electronic health records, the International Classification of Diseases, and the next update to the international guidelines.

What's actually happening hormonally to make those follicles stall?

If the follicles are not pathological cysts, what causes them to arrest in the first place? The answer is a self-reinforcing loop between your brain, your ovaries, and your pancreas.

The disruption begins centrally in your brain. There is a region that paces hormone signals to your ovaries, releasing a hormone called gonadotropin-releasing hormone (GnRH) in a specific rhythmic pulse. The frequency of that pulse determines which downstream hormones get released — a faster pulse pattern favors luteinizing hormone (LH), the signal that tells your ovaries to manufacture testosterone, while a slower pattern favors follicle-stimulating hormone (FSH), the signal that helps follicles mature. In PCOS, the pulse frequency is abnormally rapid, which drives LH up while FSH stays normal or slightly suppressed (McCartney & Campbell 2020).

When that elevated LH hits the cells in your ovaries (the theca cells), it pushes them to overproduce testosterone and other androgens. The excess local androgen concentration physically slows and disrupts the normal development of your follicles — they cannot mature past a small size in that hormonal environment.

Insulin is the massive amplifier on top of this. Insulin resistance is present in the majority of PCOS cases, independent of body weight. At the cellular level, your muscle and fat cells stop responding to insulin properly, so your pancreas pumps out significantly more insulin to keep your blood sugar stable. That high circulating insulin worsens the ovarian situation in two ways (Diamanti-Kandarakis & Dunaif 2012).

It hyper-stimulates the ovaries — insulin directly enhances the effect of LH on your theca cells, pushing them to produce even more testosterone. And it drops your liver's production of sex hormone-binding globulin (SHBG), a protein in your blood that binds up loose testosterone so it cannot drive symptoms. When SHBG drops, your exposure to free, biologically active testosterone climbs sharply.

The loop closes on itself. High insulin drives high testosterone. High testosterone stalls the follicles. The stalled follicles fail to ovulate. The lack of ovulation means no progesterone is produced to balance the hormonal milieu. And the metabolic dysfunction keeps insulin elevated.

The follicles your ultrasound picked up are the visible footprint of that loop.

Why are my AMH levels so high if these aren't real cysts?

As small arrested follicles accumulate in your ovaries, they do not just sit there silently. The cells lining those follicles (the granulosa cells) actively secrete a hormone called anti-Müllerian hormone (AMH — a hormone made by your follicles).

Because a woman with PCOS has many more of these small follicles than a woman without the condition, her circulating AMH level rises significantly. In PCOS, AMH levels are typically two to three times higher than normal reference ranges. That elevation comes from two sources: the sheer number of small follicles accumulated, and a higher rate of AMH production per individual follicle, which is itself stimulated by the high testosterone environment.

That elevated AMH then acts as a roadblock in its own right. It counteracts the brain signals that try to recruit new follicles to begin maturing, and it reduces the activity of an enzyme (aromatase) that converts androgens into estrogen — effectively locking the ovary into a high-androgen, arrested state.

For our purposes, what matters is this: the AMH reading is a direct biochemical reflection of the same arrested follicles your ultrasound is seeing. AMH does not measure a cyst. It measures the small follicles that are quietly secreting it.

That insight reshaped how the condition is diagnosed. Researchers showed that a serum AMH threshold above roughly 35 picomoles per liter (or above 5 nanograms per milliliter) is more sensitive and more specific for identifying polycystic ovarian morphology than the older follicle-count rule on ultrasound (Dewailly et al. 2011). For a deeper look at AMH itself — how it is measured, what it tells you about your fertility, and the difference between PCOS-elevated AMH and the AMH levels used to assess egg reserve — see our cluster article on what AMH actually means in PCOS.

Do I actually need a transvaginal ultrasound to be diagnosed?

For decades, getting a transvaginal ultrasound to look for "cysts" was a mandatory and often uncomfortable rite of passage for PCOS diagnosis. That has changed.

The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS — the global gold standard developed at Monash University with participation from more than 70 organizations — officially added AMH blood testing as a valid alternative to ultrasound for diagnosing polycystic ovarian morphology in adults (Teede et al. 2023). If you present with irregular cycles and clinical signs of high androgens — acne, hair thinning, unwanted facial or body hair — your clinician can now confirm the ovarian component via a simple blood test rather than requiring an invasive imaging procedure.

To prevent overdiagnosis, the guideline is explicit: a patient should be tested via ultrasound or AMH, but not both. The two tests are alternatives, not stacked confirmations. If both come back consistent with PCOS, you have not received double the evidence — you have received the same finding measured two different ways.

The shift matters most for adolescents. Because multifollicular ovaries are normal in teenagers, ultrasound is explicitly excluded from adolescent diagnostic criteria. An adolescent must show both irregular cycles and clear clinical androgen excess to be diagnosed at all — and even then, the diagnosis is often deferred for a few years to confirm the pattern is stable.

If you are an adult and have already been told you have polycystic ovaries on ultrasound, you do not need to get an AMH test to "confirm" it. If you have not yet been imaged and your clinician offers you the choice, the AMH route is non-invasive and equally diagnostic for the morphology component.

Will any of these arrested follicles ever ovulate?

This is one of the most common worries women have after a polycystic ultrasound: are my ovaries permanently broken? Have I lost those eggs?

The short version is no. The follicles arrested in PCOS are not destroyed. The eggs inside them are not damaged in a structural sense. They are paused. When the underlying drivers shift — when insulin comes down, when testosterone falls, when the brain's signaling pattern recalibrates — follicles can begin to mature normally again. Women with PCOS who address the upstream metabolic loop frequently see their cycles return, often within months of starting the right interventions.

This is also why surgical removal of the follicles was always the wrong answer. You cannot fix a hormonal feedback loop with a scalpel. The follicles your surgeon would remove are anatomically normal — what makes them "cystic" is not their structure, it is the metabolic environment they are sitting in. Remove them and the ovary will quietly produce more, because the loop driving their accumulation has not changed.

There is one historical exception worth knowing about: a surgical procedure called ovarian drilling, which was once used to induce ovulation in women with PCOS by mechanically disrupting parts of the ovary. Modern fertility medicine has moved past it for most cases because medical ovulation induction with the drug letrozole produces higher live birth rates than the historical alternatives and does not involve surgery (Franik et al. 2018). Letrozole works by temporarily blocking the conversion of androgens into estrogen, which removes a layer of negative feedback in your brain and prompts a surge of the FSH needed to mature a follicle.

If pregnancy is your goal, your reproductive endocrinologist will likely walk you through letrozole-led ovulation induction rather than any surgical approach. If pregnancy is not your immediate goal, the strategy is upstream — quiet the metabolic loop, and the follicles begin to behave again on their own.

If the follicles aren't dangerous, why does this need to be treated at all?

The follicles themselves are not the danger. The chronic anovulation behind them is.

In a healthy menstrual cycle, ovulation triggers the production of progesterone. Progesterone is the hormone that halts the proliferation of your uterine lining and eventually causes it to shed during your period. When you do not ovulate, you do not produce progesterone.

At the same time, your body continues to produce estrogen. In PCOS, estrogen exposure is often actually amplified — fat tissue contains the enzyme that converts androgens into estrogen, and because expanded visceral fat is common in PCOS, that conversion is heightened. You end up in a state clinicians call unopposed estrogen: your uterine lining receives a constant signal to grow, with no progesterone to tell it to stop and shed.

Over months and years, that constant estrogenic stimulation drives cellular overgrowth of the uterine lining (called endometrial hyperplasia), and a meta-analysis of long-term studies has shown that women with PCOS carry roughly a 2.8-fold increased risk of developing Type I endometrial cancer compared to women with regular cycles (Barry et al. 2014). The risk climbs further (around 4-fold) when the analysis is limited to premenopausal women.

This is why regulating your cycle is not just about fertility. It is a critical long-term protective measure for the uterus itself. Whether your cycle gets restored through lifestyle interventions, insulin sensitizers like metformin, or cyclic progesterone therapy prescribed by your gynecologist, ensuring the uterine lining sheds regularly is non-negotiable in PCOS management.

The "cysts" on your ultrasound were not the problem. What the cysts represented — chronic missed ovulation — is what needs attention.

How do you actually treat the root cause of the polycystic morphology?

Because the follicles are downstream of the insulin-androgen loop, treatment has to target the upstream drivers. The interventions with the strongest evidence base are not aimed at the ovaries directly — they are aimed at the metabolic environment the ovaries are operating in.

The full diagnostic and treatment framework — including which lab markers your clinician should be running and how the different PCOS presentations are categorized — is covered in our companion article on PCOS diagnosis, diet, and treatment. Below is the short list of what the evidence supports for the specific question of restoring follicle development.

Managing glycemic load

Dietary interventions are the first-line defense for lowering the insulin surges that hyper-stimulate the ovaries. The goal is not severe calorie restriction. It is managing the glycemic load of your meals — preventing the sharp postprandial blood sugar spikes that force your pancreas to release excess insulin.

A 16-week randomized controlled trial in PCOS women showed that shifting to a low-glycemic, pulse-based diet (rich in lentils, beans, and chickpeas) produced significantly greater reductions in insulin response and improvements in cholesterol profiles compared to a standard therapeutic-lifestyle diet (Kazemi et al. 2018). By flattening the insulin curve, you directly reduce the signal telling your ovaries to overproduce testosterone — which means fewer follicles get pushed into the arrested state.

Inositol supplementation at the 40:1 ratio

Inositol is a naturally occurring compound that acts as a secondary messenger for insulin signaling inside your cells. In healthy individuals, the body maintains a specific physiological ratio of two forms of inositol — myo-inositol and D-chiro-inositol — at roughly 40:1 in plasma. In PCOS, high circulating insulin disrupts how your body processes inositol, rapidly depleting the myo-inositol your ovaries need to mature follicles properly.

Clinical research shows that supplementing with the specific 40:1 ratio of myo-inositol to D-chiro-inositol restores metabolic and hormonal parameters — including ovulatory function — significantly faster than myo-inositol alone, because the 40:1 ratio reflects the intracellular concentration found in healthy ovarian follicles (Nordio & Proietti 2012). A systematic review of myo-inositol RCTs reached the same conclusion at the broader level: supplementation improves ovulatory function and reduces hyperandrogenism in PCOS women (Unfer et al. 2012).

Targeted anti-androgens to reduce the load

Spearmint tea is a well-studied botanical with anti-androgenic effects. A randomized controlled trial of hirsute women with PCOS drinking spearmint tea twice daily for 30 days showed a significant decrease in free testosterone and an increase in the brain hormones (FSH and LH) that suggest the system was re-equilibrating away from the high-androgen state (Akdoğan et al. 2007). A later RCT in 42 hirsute PCOS women replicated the testosterone reduction and showed subjective hirsutism improvement, though objective hirsutism scoring takes longer than 30 days to move (Grant 2010).

Long-chain omega-3 fatty acid supplementation (EPA and DHA from fish oil) has also been shown to significantly reduce bioavailable testosterone in women with PCOS, with the largest improvements seen in women who simultaneously lower their overall dietary omega-6 to omega-3 ratio (Phelan et al. 2011). Lowering circulating androgens lowers the local androgen concentration at the ovary, which in turn allows follicles to mature past the arrested stage.

Correcting vitamin D deficiency

Vitamin D is fat-soluble, which means it gets actively sequestered by adipose tissue. The expanded visceral fat frequently seen in PCOS acts as a sink, pulling vitamin D out of circulation and driving high rates of clinical deficiency — and that deficiency directly worsens insulin resistance.

Across 11 randomized controlled trials in PCOS women, vitamin D supplementation significantly reduced fasting glucose and improved HOMA-IR scores (a blood test that measures how insulin-resistant you actually are), with doses below 4000 IU per day producing the strongest effect (Łagowska et al. 2018). Correcting your vitamin D status removes a compounding variable in the metabolic loop driving the follicle arrest.

Stepping past the cyst fear

The renaming of PCOS to PMOS is more than a medical technicality. It is a correction of forty years of conceptual misdirection. If you have been diagnosed with this condition, you do not have ovaries filled with dangerous pathological cysts. You have a metabolic and endocrine miscommunication that is causing your normal follicles to stall before they can mature.

PCOS — under whichever name carries it through the next decade of medical literature — is heterogeneous by definition. There is no single biology, no single treatment, no single timeline. But the underlying logic is consistent: lower the insulin load, lower the androgen exposure, and the follicles begin to behave again. The arrested follicles your ultrasound picked up are not damage. They are a snapshot of where your hormones are right now. With the right upstream work, the picture changes.